Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Lower Extremity, Upper Extremity), By End Use (Hospitals & Clinics, Ambulatory care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.89 Billion
CAGR (2026-2031)	5.63%
Fastest Growing Segment	Ambulatory Care Centers
Largest Market	North America
Market Size (2031)	USD 9.57 Billion

Market Overview

The Global Venous Thromboembolism Prophylaxis Market will grow from USD 6.89 Billion in 2025 to USD 9.57 Billion by 2031 at a 5.63% CAGR. Venous thromboembolism prophylaxis constitutes the therapeutic administration of anticoagulants and the utilization of mechanical compression devices designed to avert the development of deep vein thrombosis and pulmonary embolism. The sector is fundamentally driven by an aging global demographic and a concurrent rise in hospitalization rates for major orthopedic and cardiac procedures requiring mandatory postsurgical prevention. Furthermore, the growing recognition of hospital acquired clots as a preventable cause of mortality sustains the demand for effective intervention protocols across healthcare institutions.

Despite these growth factors, the market encounters a substantial obstacle in the form of bleeding risks associated with potent pharmacological agents which can deter clinician adherence to prophylactic guidelines. This caution limits market penetration even amidst the high prevalence of clotting disorders. According to the International Society on Thrombosis and Haemostasis, in 2024, thrombosis related conditions cause one in four deaths worldwide, underscoring the vital importance of balancing efficacy with safety in expanding the adoption of prophylactic measures.

Key Market Drivers

The growing volume of orthopedic and major surgical procedures acts as a primary catalyst for the market, necessitating rigorous postsurgical prevention strategies to manage patient safety. As healthcare systems recover from pandemic-induced backlogs, the frequency of high-risk interventions such as total hip and knee arthroplasties has surged, directly increasing the utilization of mechanical compression and pharmacological prophylaxis. This uptick in surgical throughput compels hospitals to stock and administer prophylactic solutions to mitigate the elevated risk of deep vein thrombosis inherent in prolonged immobilization and operative trauma. According to Stryker, January 2024, in the 'Fourth Quarter 2023 Operating Results', the company reported that net sales grew by 11.5 percent to $5.8 billion, a performance attributed largely to the sustained momentum in surgical procedure volumes which necessitates concurrent preventative care.

Concurrently, the rapid adoption of Novel Oral Anticoagulants (NOACs) is reshaping the standard of care by offering improved safety profiles and ease of administration compared to traditional vitamin K antagonists. Clinicians are increasingly favoring these advanced therapies for their predictable pharmacokinetics, which reduces the need for constant monitoring and enhances patient compliance with prophylactic regimens. According to Bristol Myers Squibb, February 2024, in the '2023 Annual Report', the leading oral anticoagulant Eliquis generated worldwide revenues of $12.2 billion, reflecting the substantial global shift toward these modern therapeutic agents. This transition is further emphasized by the persistent burden of the condition; according to the National Blood Clot Alliance, in 2024, blood clots affect approximately 900,000 people in the United States each year, driving the urgency for reliable and effective prophylactic interventions across the continuum of care.

Download Free Sample Report

Key Market Challenges

The Global Venous Thromboembolism Prophylaxis Market faces a distinct impediment in the form of major bleeding risks associated with the administration of potent anticoagulant therapies. Clinicians are often compelled to weigh the benefits of clot prevention against the potential for life-threatening hemorrhagic complications, particularly in vulnerable demographics such as the elderly or those recovering from extensive surgery. This clinical dilemma frequently results in the under-prescription of necessary pharmacological prophylaxis, reduced dosages, or the premature cessation of therapy. Such caution, while clinically justified, directly restricts the volume of anticoagulants utilized and dampens the adoption rates of prophylaxis protocols, thereby limiting the overall market expansion.

This constraint is particularly acute within high-risk patient populations that represent a significant portion of the addressable market. According to the American Society of Hematology, in 2023, medical inpatients and long-term care residents accounted for approximately 20% to 25% of all venous thromboembolism instances globally. Since these specific groups often present with comorbidities that exacerbate bleeding susceptibility, the rigorous application of prophylaxis is frequently compromised by safety concerns, effectively curbing market penetration in a sector that otherwise drives substantial demand for preventative interventions.

Key Market Trends

The proliferation of wearable and portable mechanical prophylaxis devices is altering the recovery landscape by decoupling compression therapy from stationary hospital infrastructure. Unlike traditional pneumatic systems that tether patients to bedside units, these battery-operated devices enable early mobilization, which is critical for reducing venous stasis and improving patient adherence during the post-discharge phase. This shift supports the growing demand for home-based recovery solutions that maintain clinical efficacy without restricting patient mobility. The market viability of these technologies is evident in the financial performance of key sector players. According to Enovis Corporation, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Results', the company's Prevention and Recovery segment achieved a full-year net sales growth of 5%, reflecting the sustained demand for these mobile therapeutic solutions.

Concurrently, the implementation of personalized prophylaxis protocols via AI-driven risk assessment is replacing generic prevention strategies with precision medicine tools. Advanced algorithms now integrate with electronic health records to continuously monitor patient data, automatically flagging high-risk individuals who might be overlooked by manual scoring systems like Caprini or Padua. This automation ensures timely intervention for conditions such as pulmonary embolism and streamlines care coordination across fragmented hospital departments. The rapid integration of these intelligent systems is reflected in the expanding footprint of specialized AI providers. According to Viz.ai, January 2024, in the 'Viz.ai Adoption Surpasses 1,500 Hospitals Nationwide' press release, the user base for its AI-powered disease detection platform grew by nearly 30% in 2023 to reach 45,000 healthcare providers.

Segmental Insights

Ambulatory Care Centers represent the fastest-growing segment within the Global Venous Thromboembolism Prophylaxis Market due to a significant structural shift in healthcare delivery toward outpatient services. This growth is largely accelerated by the rising preference for same-day surgeries which substantially reduce hospital stays and associated operational costs. Furthermore, initiatives by major institutions such as the Centers for Medicare & Medicaid Services encourage this transition by offering favorable reimbursement policies for outpatient procedures. As high-risk surgical volumes increase in these settings, the requirement for rigid thrombosis prevention protocols has intensified to ensure patient safety following discharge.

Regional Insights

North America maintains a leading position in the global venous thromboembolism prophylaxis market due to its well-established healthcare infrastructure and high diagnosis rates. The region faces a rising prevalence of deep vein thrombosis and pulmonary embolism, particularly among the aging population and patients undergoing major orthopedic surgeries. Additionally, the proactive role of the U.S. Food and Drug Administration in approving novel oral anticoagulants and mechanical devices accelerates the adoption of advanced therapies. The strong presence of major pharmaceutical and medical device manufacturers further supports market expansion by ensuring the consistent availability of preventative treatments.

Recent Developments

• In November 2024, Cardinal Health announced the U.S. launch of its Kendall SCD SmartFlow Compression System, a next-generation device for venous thromboembolism (VTE) prophylaxis. The system features Vascular Refill Detection technology, which customizes compression cycles to the patient’s unique physiology, thereby moving more blood per hour than uniform compression models. Designed to improve clinician workflow and patient comfort, the device addresses the critical need for effective mechanical prophylaxis in hospitalized patients at risk of deep vein thrombosis and pulmonary embolism. This launch reinforces the company’s position in the mechanical VTE prevention market.
• In November 2024, Anthos Therapeutics presented new findings from the AZALEA-TIMI 71 study at the American Heart Association Scientific Sessions. The research demonstrated that the investigational Factor XI inhibitor abelacimab significantly reduced bleeding events by 67% compared to rivaroxaban in patients receiving background antiplatelet therapy. These results support the potential of abelacimab to decouple hemostasis from thrombosis, offering a safer profile for high-risk patients. This breakthrough underscores the promise of Factor XI inhibitors as a new class of therapies in the global venous thromboembolism prophylaxis and anticoagulation market, addressing the unmet need for safer bleeding profiles.
• In November 2024, Bristol Myers Squibb and Johnson & Johnson presented updated data on their investigational oral Factor XIa inhibitor, milvexian, at the American Heart Association Scientific Sessions. The companies highlighted the progress of the Phase 3 Librexia clinical program, which investigates the drug's efficacy in preventing thrombotic events across multiple indications. The presentation emphasized the potential of milvexian to reduce the risk of thrombosis without significantly increasing bleeding, a key safety advantage over current anticoagulants. This research is pivotal for the future of the global venous thromboembolism prophylaxis and anticoagulation market as the companies continue their strategic collaboration.
• In September 2024, Bayer presented detailed results from the Phase 3 OCEANIC-AF clinical trial at the European Society of Cardiology Congress. The study evaluated the investigational oral Factor XIa inhibitor asundexian compared to apixaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The data revealed that asundexian was inferior to the standard-of-care anticoagulant, leading to the trial's early termination. This breakthrough research provides critical insights into the efficacy thresholds of Factor XI inhibition, influencing the development strategies for next-generation anticoagulants in the venous thromboembolism prophylaxis and stroke prevention markets.

Key Market Players

• Arjo
• Encompass Group
• Argon Medical Devices
• MEGO AFEK
• Zenith Technical Innovations
• Cook Medical
• Bio Compression Systems
• ThermoTek USA
• Boston Scientific Corporation
• Cardinal Health

By Type	By End Use	By Region
Lower Extremity Upper Extremity	Hospitals & Clinics Ambulatory care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Venous Thromboembolism Prophylaxis Market, By Type:

• Lower Extremity
• Upper Extremity

• Venous Thromboembolism Prophylaxis Market, By End Use:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

• Venous Thromboembolism Prophylaxis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE